Thyroid function on admission and outcome in patients hospitalized for acute decompensated heart failure  by Okayama, Dai et al.
Journal of Cardiology 66 (2015) 205–211Original article
Thyroid function on admission and outcome in patients hospitalized
for acute decompensated heart failure
Dai Okayama (MD), Yuichiro Minami (MD)*, Shohei Kataoka (MD), Tsuyoshi Shiga (MD),
Nobuhisa Hagiwara (MD, FJCC)
Department of Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
A R T I C L E I N F O
Article history:
Received 26 February 2015
Received in revised form 2 April 2015
Accepted 9 April 2015






A B S T R A C T
Background: Although thyroid dysfunction is a known prognostic factor for cardiovascular disease, the
relationship between thyroid function and prognosis in patients with acute decompensated heart failure
(ADHF) is poorly understood. Herein, we investigated the association between thyroid hormone levels
and outcome in patients hospitalized for ADHF.
Methods: We evaluated 270 hospitalized ADHF patients with thyroid hormone levels measured at
admission between April 2007 and May 2012.
Results: The median (interquartile range) thyroid stimulating hormone, free triiodothyronine (fT3), and
free thyroxine were 2.79 (1.49–4.96) mU/ml, 2.32 (1.93–2.75) pg/ml, and 14.0 (12.1–15.7) pg/dl,
respectively. Receiver operating characteristic (ROC) curve analysis was applied to assess their
prognostic value for in-hospital outcome. The fT3 had the most favorable performance, with an area
under the ROC curve of 0.791 (optimal cutoff point 2.05; sensitivity 85.0%; speciﬁcity 72.0%). Although
patients in the low fT3 group (2.05) had higher age and lower body mass index, there were no
signiﬁcant differences with respect to systolic blood pressure and heart rate between the groups. In
multivariate analysis adjusted for various markers of disease severity and amiodarone use, low fT3 level
was independently associated with higher in-hospital mortality (odds ratio 14.4; p < 0.001). In addition,
the probability of 1-year total death among patients with low fT3 was signiﬁcantly higher than that
among patients with normal fT3 (log-rank p < 0.001).
Conclusions: Low fT3 level was associated with adverse outcomes in patients hospitalized for ADHF.
Thyroid hormone measurements might be useful in the risk stratiﬁcation of ADHF patients.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Acute decompensated heart failure (ADHF) is a common but
poorly deﬁned clinical syndrome in cardiovascular and emergency
medicine, and is associated with a poor outcome [1,2]. In addition,
ADHF is the most common cause of hospitalization in patients
older than 65 years, and rates will continue to increase in the future
[1,2]. However, assessment of prognosis in individual ADHF
patients remains challenging because of the high variability in
the clinical course of the disease [3–7].DOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2015.05.001
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsThyroid hormone affects the function of all cells, tissues, and
organs, including the heart [8–11]. Previous studies have
elucidated that altered thyroid hormone metabolism, such as
low serum free triiodothyronine (fT3) concentration, was
described in patients with cardiovascular disease including heart
failure [8,12,13]. A low fT3 was associated with higher right atrial,
pulmonary artery, and pulmonary capillary wedge pressures, and
lower ejection fraction and cardiac index [12]. In addition,
thyroid dysfunction may inﬂuence outcome in patients with
cardiovascular disease, because the cardiovascular system is a
key target of thyroid hormone [13–23]. However, the relationship
between thyroid dysfunction and clinical outcomes in patients
with established chronic heart failure remains controversial
[14,16–18,20,23]. Furthermore, an association of thyroid function
with outcome in patients with acute decompensated phase of
heart failure is poorly understood. Thus, we investigated the
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Fig. 1. Receiver operating characteristic (ROC) curves predicting the in-hospital all-
cause death for hospitalized patients with acute decompensated heart failure. The
area under the ROC curve (AUC) for thyroid stimulating hormone (TSH) (A) was
0.580, for free triiodothyronine (fT3) (B) was 0.791, and for free thyroxine (fT4) (C)
was 0.552.
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ized for ADHF.
Methods
Patients and thyroid function measurements
We retrospectively evaluated 367 consecutive hospitalized
patients who suffered from ADHF who were referred to the Cardiac
Intensive Care Unit at Tokyo Women’s Medical University Hospital,
Tokyo, Japan, between April 2007 and May 2012. The diagnosis of
heart failure was assessed based on modiﬁed Framingham criteria
[24]. ADHF was deﬁned as new onset of decompensated heart
failure or decompensation of chronic, established heart failure
meeting the criteria and sufﬁcient to warrant hospitalization and
urgent therapy. Patients were certiﬁed for enrollment if they
were hospitalized for episodes of ADHF as the primary cause of
admission. Patients aged less than 20 years old and those with
acute coronary syndrome were excluded. The study was
performed according to the principles of the Declaration of
Helsinki, and this study protocol was approved by our institutional
ethics committee.
Thyroid hormone levels [thyroid stimulating hormone (TSH),
fT3, and free thyroxine (fT4)] were measured in hospitalized
ADHF patients within 48 h after admission. A total of 97 patients
were excluded from this analysis because of missing thyroid
hormone measurements (n = 92), overt primary hypothyroidism
(TSH > 10 mU/ml and fT4 < 6 pg/ml with or without thyroid
replacement therapy) (n = 3), and overt primary hyperthyroidism
(fT3 > 4.5 pg/ml or fT4 > 23 pg/ml with undetectable TSH levels)
(n = 2) [14]. Therefore, the ﬁnal study population consisted of
270 patients hospitalized for ADHF.
Follow-up and end-points
Follow-up started from the day of ADHF admission. Follow-up
data were obtained from the following sources: reviewing our
hospital records, periodically examining patients in the outpatient
clinic, contacting patients’ physicians, or interviewing the patients
by phone. Complete information on the follow-up data was
ascertained for 362 (98.6%) of the total 367 patients. The end-point
of this study was in-hospital and 1-year all-cause death, cardiac
death, and non-cardiac death. All end-points were ascertained by
two experienced physicians who were not study investigators.
Statistical analysis
Analyses were performed with the SAS ver. 9.1 (SAS Institute,
Cary, NC, USA) by an independent biostatistics and data center
(STATZ Institute, Inc., Tokyo, Japan). Results are presented as
the mean with standard deviation (SD), median with interquartile
range, or frequencies (%). Student’s t-test was used to compare
normally distributed continuous variables between groups.The
Mann–Whitney U-test was used for skewed continuous or ordinal
variables. The chi-square test or Fisher’s exact test (when an
expected value was less than 5) was used to compare nominal
variables. Sensitivity and speciﬁcity were calculated according to
standard deﬁnitions. Receiver operating characteristic (ROC)
curves were constructed and the area under the ROC curve was
calculated to assess the usefulness of the thyroid hormone levels
for predicting the in-hospital outcome. Best cutoff values were
identiﬁed by ROC curves with Youden index. To evaluate the
impact of low fT3 on the in-hospital prognosis, univariate and
multivariate logistic regression models were used. Multivariate
models included the age, sex, body mass index, systolic blood
pressure, B-type natriuretic peptide, serum sodium, creatinine,blood urea nitrogen, hemoglobin, C-reactive protein, and amio-
darone use before admission. The probability of 1-year all-cause,
cardiac, and non-cardiac death was estimated by the Kaplan–Meier
method, after which the log-rank test was used to compare
survival curves. Two-tailed p-values of less than 0.05 were
considered to indicate statistical signiﬁcance.
Results
Thyroid function proﬁle
The median (interquartile range) serum concentrations of TSH,
fT3, and fT4 were 2.79 (1.49–4.96) mU/ml, 2.32 (1.93–2.75) pg/ml,
and 14.0 (12.1–15.7) pg/ml, respectively, in 270 hospitalized
patients with ADHF. ROC curve analysis was applied to assess
their prognostic value for in-hospital all-cause death (Fig. 1). As a
result, fT3 showed the most favorable performance, and the area
under the ROC curve for TSH was 0.580 (optimal cutoff point
>2.78; sensitivity 70.0%; speciﬁcity 51.6%, Fig. 1A), for fT3 was
0.791 (optimal cutoff point 2.05 pg/ml; sensitivity 85.0%;
speciﬁcity 72.0%, Fig. 1B), and for fT4 was 0.552 (optimal cutoff
point 16.1; sensitivity 95.2%; speciﬁcity 19.6%, Fig. 1C). Box-and-
whisker plots of fT3 levels at admission in ADHF patients with or
without end-point (in-hospital all-cause death) are shown in
Fig. 2. In patients who died during hospitalization, fT3 at admission
Fig. 2. Box-and-whisker plots of free triiodothyronine (fT3) levels at admission in
acute decompensated heart failure patients with or without end-point (in-hospital
all-cause death). The line across each box represents the median fT3, the box
represents the interquartile range (25th–75th percentile), and the I-bars represent
the 95% conﬁdence intervals.
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who remained alive during hospitalization [2.37 (2.00–2.76) pg/
ml] (p = 0.002).
In-hospital outcome
Among the 87 patients in the low fT3 group, 17 (19.5%) died
during hospitalization including 9 (10.3%) with cardiac cause
(8 with death from heart failure and 1 with death due to infective
endocarditis) and 8 (9.2%) with non-cardiac cause (4 with
pneumonia and respiratory failure, 3 with other infectious disease
including sepsis, and 1 with gastrointestinal bleeding). By contrast,
only 3 out of 183 patients (1.6%) in the normal fT3 group died in-
hospital including 2 (1.1%) with cardiac death from heart failure
and 1 (0.5%) with non-cardiac death due to cerebrovascular
disorders. In univariate analysis, low fT3 level (2.05 pg/ml) on
admission was associated with higher in-hospital all-cause death
rate (crude odds ratio 14.6; p < 0.001), cardiac death rate (crude
odds ratio 10.4; p = 0.003), and non-cardiac death rate (crude odds
ratio 18.4; p = 0.006) (Table 1). In addition, low fT3 level was
independently associated with higher in-hospital all-cause mor-
tality (adjusted odds ratio 14.4; p < 0.001), cardiac death rate
(adjusted odds ratio 9.62; p = 0.037), and non-cardiac death rate
(adjusted odds ratio 17.1; p = 0.016) in multivariate analysisTable 1






Total death Normal fT3 183 3 (1.6%) 1.00 
Low fT3 87 17 (19.5%) 14.57 (
Cardiac death Normal fT3 183 2 (1.1%) 1.00 
Low fT3 87 9 (10.3%) 10.44 (
Non-cardiac death Normal fT3 183 1 (0.5%) 1.00 
Low fT3 87 8 (9.2%) 18.43 (
Multivariate models included the age, sex, body mass index, systolic blood pressu
hemoglobin, C-reactive protein, and amiodarone use before admission. fT3, free triioadjusted for various markers of disease severity and amiodarone
use (Table 1). When in-hospital all-cause and cardiac deaths were
considered, systolic blood pressure (per 1 mmHg increase,
adjusted odds ratio for all-cause death 0.97; p = 0.012, adjusted
odds ratio for cardiac death 0.96; p = 0.049) and hemoglobin level
(per 1 g/dl increase, adjusted odds ratio for all-cause death 0.60;
p = 0.017, adjusted odds ratio for cardiac death 0.48; p = 0.016) on
admission were other independent predictors for outcome in
multivariate analysis. However, low fT3 was the only independent
predictor for in-hospital non-cardiac death in multivariate
analysis.
Baseline characteristics
Baseline clinical characteristics according to thyroid status on
admission based on fT3 levels are shown in Table 2. Although
patients in the low fT3 group (2.05 pg/ml) had higher age and
lower body mass index, there were no signiﬁcant differences with
respect to systolic blood pressure and heart rate between the
groups. The prevalence of jugular venous distension was signiﬁ-
cantly higher in patients in the low fT3 group. In addition, patients
in the low fT3 group had higher B-type natriuretic peptide, blood
urea nitrogen, serum creatinine, and C-reactive protein levels, and
lower serum sodium and hemoglobin levels, than those in the
normal fT3 group (>2.05 pg/ml). Further, patients in the low fT3
group were more likely to be taking loop diuretics, amiodarone,
and hemodialysis before ADHF admission.
One-year outcomes
Among the 87 patients in the low fT3 group, 26 (29.9%) died
during the 1-year follow-up period including 16 (18.4%) with
cardiac cause (12 with death from heart failure, 3 with sudden
cardiac death, and 1 with death due to infective endocarditis) and
10 (11.5%) with non-cardiac cause (4 with pneumonia and
respiratory failure, 3 with other infectious disease including
sepsis, 2 with malignancy, and 1 with gastrointestinal bleeding). In
contrast, 26 out of 183 patients (14.2%) in the normal fT3 group
died during the 1-year follow-up period, including 15 (8.2%) with
cardiac death (8 with death from heart failure and 7 with sudden
cardiac death) and 11 (6.0%) with non-cardiac death (1 with
cerebrovascular disorders, 2 with pneumonia and respiratory
failure, 2 with other infectious disease including sepsis, 4 with
malignancy, and 2 with gastrointestinal bleeding). One-year
Kaplan–Meier survival curves for cumulative all-cause, cardiac,
and non-cardiac death in patients with low fT3 level versus normal
fT3 level (>2.05 pg/ml) are shown in Fig. 3. The probability of
1-year all-cause, cardiac, and non-cardiac death among patients
with low fT3 level was signiﬁcantly higher than that among
patients with normal fT3 level (log-rank p < 0.001, p < 0.001, and
p = 0.015, respectively).Univariate Multivariate
ds ratio (95% CI) p-value Adjusted odds ratio (95% CI) p-value
1.00
4.14–51.26) <0.001 14.38 (2.95–70.00) <0.001
1.00
2.21–49.44) 0.003 9.62 (1.15–80.33) 0.037
1.00
2.27–149.84) 0.006 17.08 (1.71–170.69) 0.016
re, B-type natriuretic peptide, serum sodium, creatinine, blood urea nitrogen,
dothyronine.
Table 2
Baseline characteristics according to thyroid status on admission based on fT3 levels.
Characteristics Normal fT3 >2.05 pg/ml (N = 183) Low fT3 2.05 pg/ml (N = 87) p-value
Age (years) 65.0  16.0 72.3  14.9 <0.001
Women, n (%) 55 (30.1) 30 (34.5) 0.464
Etiology of heart failure, n (%) 0.126
Ischemic 54 (29.5) 33 (37.9)
Hypertensive 13 (7.1) 12 (13.8)
Idiopathic 37 (20.2) 8 (9.2)
Valvular 32 (17.5) 15 (17.2)
Others 47 (25.7) 19 (21.8)
Medical history, n (%)
Prior hospitalization for heart failure 82 (44.8) 48 (55.2) 0.130
Hypertension 104 (56.8) 57 (65.5) 0.174
Dyslipidemia 91 (49.7) 34 (39.1) 0.101
Diabetes mellitus 75 (41.0) 35 (40.2) 0.906
Smoking 82 (44.8) 28 (32.2) 0.089
Ventricular tachycardia or ﬁbrillation 51 (27.9) 25 (28.7) 0.882
Pacemaker or implantable cardioverter deﬁbrillator 23 (12.6) 18 (20.7) 0.082
Cardiac resynchronization therapy 8 (4.4) 9 (10.3) 0.059
Stroke or transient ischemic attack 31 (16.9) 9 (10.3) 0.154
Chronic obstructive pulmonary disease or asthma 20 (10.9) 10 (11.5) 0.890
Hemodialysis 3 (1.6) 6 (6.9) 0.025
Medications prior to admission, n (%)
Loop diuretics 83 (45.4) 54 (62.1) 0.010
Aldosterone antagonists 59 (32.2) 32 (36.8) 0.461
Thiazide diuretics 22 (12.0) 14 (16.1) 0.358
Angiotensin-converting enzyme inhibitors 29 (15.8) 11 (12.6) 0.489
Angiotensin receptor blockers 79 (43.2) 42 (48.3) 0.430
Calcium channel blockers 43 (23.5) 18 (20.7) 0.606
Beta blockers 90 (49.2) 39 (44.8) 0.503
Digitalis 40 (21.9) 19 (21.8) 0.997
Nitrates 47 (25.7) 29 (33.3) 0.191
Aspirin 62 (33.9) 31 (35.6) 0.777
Warfarin 68 (37.2) 26 (29.9) 0.241
Amiodarone 21 (11.5) 18 (20.7) 0.044
Statins 64 (35.0) 23 (26.4) 0.161
Initial clinical ﬁndings
Paroxysmal nocturnal dyspnea, n (%) 76 (41.5) 38 (43.7) 0.758
Orthopnea, n (%) 113 (61.7) 56 (64.4) 0.717
Rales, n (%) 103 (56.3) 45 (51.7) 0.424
Third heart sound, n (%) 66 (36.1) 34 (39.1) 0.597
Jugular venous distension, n (%) 67 (36.6) 41 (47.1) 0.044
Peripheral edema, n (%) 116 (63.4) 54 (62.1) 0.881
Left ventricular ejection fraction 40%, n (%) 118 (64.5) 62 (71.3) 0.294
Atrial ﬁbrillation, n (%) 76 (41.5) 31 (35.6) 0.354
Body mass index (kg/m2) 24.0  4.2 22.1  3.9 <0.001
Heart rate (beats/min) 95.4  28.0 89.1  23.4 0.070
Systolic blood pressure (mmHg) 138.1  33.3 130.8  42.0 0.123
B-type natriuretic peptide (pg/mla) 750 [390–1237] 940 [530–1810] 0.002
Blood urea nitrogen (mg/dl) 26.1  17.3 38.4  23.9 <0.001
Serum creatinine (mg/dl) 1.29  0.99 1.81  1.31 <0.001
Serum sodium (mEq/l) 139.2  4.0 137.4  5.5 0.002
Hemoglobin (g/dl) 12.8  2.4 11.5  2.0 <0.001
C-reactive protein (mg/dla) 0.59 [0.18–1.46] 1.22 [0.32–3.89] <0.001
Total bilirubin (mg/dla) 0.8 [0.6–1.3] 0.9 [0.5–1.4] 0.356
Length of hospital stay (daysa) 26 [15–47] 30 [18–51] 0.346
Plus minus value: mean  SD. fT3, free triiodothyronine.
a Median [interquartile range].
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In this study, we identiﬁed fT3 as a useful prognostic marker in
patients hospitalized for ADHF, while fT3 was superior to other
thyroid hormones including TSH and fT4. In multivariate analysis
adjusted for various markers of disease severity and amiodarone
use, low fT3 level on admission was independently associated with
higher in-hospital all-cause, cardiac, and non-cardiac death rates.
In addition, lower fT3 was associated with increased medium-term
(1-year) mortality in ADHF patients.
Thyroid hormone affects every cell, tissue, and organ in the
body, and its homeostasis has a fundamental role in normal
cardiac function [8–11]. The majority of serum thyroid hormones(95–99%) are bound to the carrier proteins including thyroxin-
binding globulins, transthyretin, and albumin, which carry 75%,
20%, and 5%, respectively, of thyroid hormones within blood
circulation, while a small fraction circulates unbound or free
[25,26]. The free or unbound fraction of thyroid hormone is
responsible for its biological functions in all tissues, with the
major cardiovascular effects regulated by fT3, which increases
tissue thermogenesis, cardiac contractility, heart rate, and
cardiac output, and decreases systemic vascular resistance
including that of the coronary artery [8,9,11]. As such, reduced
fT3 levels may have adverse effects on the cardiovascular system,
and thus cause poor prognosis in patients with cardiovascular
disease [13,14,16].
Fig. 3. Outcomes in acute decompensated heart failure patients with low or normal free triiodothyronine (fT3) levels. Kaplan–Meier estimate of all-cause death (A), cardiac
death (B), and non-cardiac death (C) in 87 patients with low fT3 compared with 183 patients with normal fT3.
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between TSH levels and outcomes in patients with chronic
congestive heart failure [18,20,23]. However, the prognostic value
of TSH remains controversial. For example, both elevated and
suppressed TSH values were associated with an increased risk of
death in patients with chronic heart failure, even after adjustment
for other prognostic markers [18]. By contrast, abnormal TSH levels
were not found to be an independent predictor of death in chronic
heart failure patients from a randomized controlled trial cohort
[20]. With respect to the association between fT3 and outcomes in
patients with chronic congestive heart failure, the prognostic valueof low fT3 has been reported in several studies. For example,
Pingitore et al. and Kozdag et al. reported that low fT3 was an
independent predictor of adverse outcomes [14,16]. Thus, we
suggest that the prognostic value of low fT3 for predicting
outcomes in patients with chronic phase congestive heart failure is
superior to use of TSH levels. In the present study, lower fT3 level
without overt thyroid dysfunction (low-T3 syndrome) on admis-
sion was a strong predictor of in-hospital and 1-year mortality, in
terms of both cardiac causes and non-cardiac causes, in patients in
the acute phase of decompensated heart failure needing urgent
hospitalization and treatment. These ﬁndings expand upon
D. Okayama et al. / Journal of Cardiology 66 (2015) 205–211210previous knowledge of the prognostic implication of fT3 value in
patients with heart failure.
A typical pattern of altered thyroid hormone metabolism,
characterized by low serum fT3 concentration, was described in
patients with non-thyroidal illnesses, including acute myocardial
infarction, adults and children after cardiopulmonary bypass, and
heart failure [12,27–29]. The pathophysiological role of low-T3
syndrome is commonly interpreted as an ‘adaptive’ compensatory
and beneﬁcial response, which decreases metabolic demand in
diseased states [30]. Reduced fT3 is more frequent in patients with
NYHA III–IV severe heart failure, and is frequently related to a
catabolic pattern characterized by lower plasma lipid levels, body
weight, albumin levels, and lower cardiac index with increased left
ventricular end diastolic pressure [10]. In the present study,
patients with low fT3 had signiﬁcantly higher age, B-type
natriuretic peptide, and creatinine levels, and lower body mass
index and hemoglobin levels, compared with patients with normal
fT3. These data suggest that low fT3 may be an adaptive response
to severely reduced conditions. This interpretation, however, has
been questioned in recent years. Numerous reports, including the
present study, have found that low-T3 syndrome is a strong
independent predictor of poor outcome in hospitalized patients
with cardiac disease and ADHF, even after multivariate analysis
adjusted for various markers of disease severity [13,14,16]. Based
on knowledge of the fundamental role of fT3 on cardiovascular
homeostasis, a direct relationship between low-T3 syndrome and
adverse outcome in patients with heart disease represents an
attractive ‘mal-adaptation’ hypothesis. Because thyroid hormone
action in the myocardium is via speciﬁc T3 receptors, low fT3 levels
may worsen contractility, increase susceptibility to arrhythmias,
and contribute to mortality in patients with heart failure despite
normal T4 and TSH levels suggesting a euthyroid state [31]. A
previous study demonstrated that a short-term intravenous
infusion of T3 is well tolerated in patients with advanced heart
failure, and there was an increase in cardiac output and a reduction
in systemic vascular resistance, without change in blood pressure
or heart rate [32]. In addition, short-term T3 replacement therapy
signiﬁcantly improved not only ventricular performance, but also
the neuroendocrine proﬁles including noradrenaline, N-terminal
pro-B-type natriuretic peptide, and aldosterone levels in patients
with ventricular dysfunction and low-T3 syndrome [33]. Further-
more, one week of oral T3 administration in patients with milder
heart failure has been shown to cause a moderate increase in left
ventricular ejection fraction and exercise tolerance [34]. Although
several inotropic agents have been shown to have deleterious
effects on long-term survival, T3 has unique cellular mechanisms
of action [35] that may not be associated with similar outcomes.
Additional studies are required to clarify whether the decreased
fT3 concentration is an ‘adaptive’ beneﬁcial response or ‘maladap-
tive’ adverse process. Further, larger-scale multicenter and/or
multinational randomized controlled trials are needed to deﬁne
the effects of T3 replacement therapy in patients with heart failure.
Cardiac cachexia and poor nutritional status is a serious
complication of heart failure, and is associated with poor prognosis
[36]. In this study, patients in the low fT3 group had higher blood
urea nitrogen, B-type natriuretic peptide, and C-reactive protein
levels, and had lower body mass index, sodium, and hemoglobin
levels than those in the normal fT3 group. Similarly, patients with
cachexia had higher B-type natriuretic peptide and C-reactive
protein levels, and had lower body mass index and hemoglobin
levels than those without [36]. Above results suggest that reported
characteristics of patients with cachexia were similar to those with
low fT3 in this study. In addition, poor nutritional status may also
contribute to altered thyroid metabolism in heart failure patients,
because T3 production is known to be reduced in the fasting state
[12,37]. Accordingly, it is our impression that there are manyunanswered questions about the relationship between low fT3,
cardiac cachexia, and prognosis in patients hospitalized for ADHF.
Although our multivariate models included nutritional markers
such as body mass index, B-type natriuretic peptide, serum
sodium, blood urea nitrogen, hemoglobin, and C-reactive protein,
further investigation is required to clarify the association of
thyroid functional and nutritional status with the outcome of
hospitalized ADHF patients.
There are several limitations to the present study. First, this is a
single-center observational study with a limited number of study
patients, making it difﬁcult to establish causal relationships.
Second, even with adjustments by multivariate analysis, we cannot
exclude the possibility that residual measured and/or unmeasured
confounders may have inﬂuenced our results. Third, the measure-
ment of thyroid hormone was not performed in all ADHF patients,
and was dependent on the physician’s judgment, which introduces
the potential for selection bias. Fourth, as we did not have follow-
up thyroid function data, the prevalence and prognostic impact of
persisting thyroid function abnormality in this study population
are unclear. Fifth, as we have no data on thyroid sonography or
autoantibodies, the prevalence of autoimmune thyroid disorders in
this study ADHF cohort is unclear. Finally, right heart catheteriza-
tion, exercise tolerance capacity, and detailed echocardiographic
study were not performed in all the study patients, and we cannot
demonstrate more detailed echocardiographic, hemodynamic, and
exercise tolerance data in this ADHF cohort.
Conclusions
Low fT3 levels on admission were associated with in-hospital
short-term outcome and 1-year medium-term prognosis in
patients hospitalized for ADHF. Thyroid hormone measurements
might be useful in the risk stratiﬁcation of hospitalized ADHF
patients.
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